'Report predicts multiple sclerosis drug market will reach $15.8bn in 2015' says Visiongain

A new report by visiongain predicts that revenues for disease-modifying treatments for multiple sclerosis (MS) will rise to $15.8bn annually in 2015. That analysis appears in Multiple Sclerosis Treatment: World Drug Market 2012-2022.
Spread the Word
Listed Under

Scm Pharma


London City - London, Greater - England

Nov. 25, 2011 - PRLog -- Visiongain forecasts that the MS drug industry and market will expand to 2015. There will be strong revenue growth in established and developing pharmaceutical markets, especially the US, Japan and the UK. The MS treatment market will change with the launch of new agents that slow symptom progression and reduce relapse rates.

John O'Neill, a pharmaceutical industry analyst at visiongain, said: "Entry of more-efficacious treatments to the MS drug market - and drugs that can be taken orally rather than injected - will expand the treated patient population. There is scope for important developments in national markets such as the UK, where the number of MS patients is high and treatment can be improved."

In particular, this new study predicts the future of the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya, showing revenue forecasts to 2022. The report discusses companies such as Biogen Idec, Teva, Sanofi, Novartis, Merck Serono and Bayer. It also assesses the R&D pipeline for treating multiple sclerosis and forecasts leading national markets.

With a strong R&D pipeline, the MS treatment market will expand this decade. Products from its pipeline will help patients, as will extensions of the indication ranges for marketed drugs. Multiple Sclerosis Treatment: World Drug Market 2012-2022 adds to visiongain's range of analytical research reports on immune disorders, neurodegenerative disorders and other therapeutic areas.

To see report sample pages please visit http://www.visiongain.com/Report/723/Multiple-Sclerosis-T...
Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44 020 7336 6100


Notes for Editors

If pvjjq you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

# # #

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Email:***@visiongain.com Email Verified
Phone:+44 020 7336 6100
Zip:EC1V 2QY
Tags:Pharmaceutical, Conctract, Api, Cmo, R D, US, Kemwell, Qbd, Gmp, Scm Pharma
Industry:Medical, Health, Business
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share